Business Wire

ADVA introduces multi-layer cell site gateway to maximize 5G efficiency

5.9.2019 10:00:00 EEST | Business Wire | Press release

Share

ADVA (FSE: ADV) today launched its FSP 150-XG118Pro, a cell site gateway device specifically designed to meet the challenges of 5G. Ideal for deployment at radio base stations, the ADVA FSP 150-XG118Pro meets urgent demand for ultra-reliable low-latency communications (URLLC) in 5G mobile networks and supports a smooth transition from 1Gbit/s to 10Gbit/s services. The solution also features a temperature-hardened design and precise synchronization capabilities. What’s more, with its industry-leading demarcation technology and pluggable high-performance server, the FSP 150-XG118Pro enables virtual network functions (VNFs) to be hosted at the edge of the network and gives communication service providers (CSPs) and mobile wholesale operators a risk-free route to network functions virtualization (NFV).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905005062/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The ADVA FSP 150-XG118Pro is the ultimate tool for rapid 5G rollouts over existing LTE infrastructure (Photo: Business Wire)

“Our FSP 150-XG118Pro brings high-capacity demarcation and edge aggregation to the radio base station without exceeding strict requirements for space, power and cost. It really is the ultimate tool for rapid 5G rollouts over existing LTE infrastructure,” said Richard Strike, director, product line management, ADVA. “Our FSP 150-XG118Pro empowers mobile network operators (MNOs) to respond to soaring bandwidth needs with 10Gbit/s bandwidth at the radio base station. They can also cater for new URLLC applications that demand data to be processed right where it’s created. And, as the solution has been built with our Oscilloquartz team of network synchronization specialists, it delivers the accurate and stable timing that’s so crucial for 5G applications.”

The ADVA FSP 150-XG118Pro has been specifically engineered to support a seamless, cost-efficient transition from LTE mobile networks to 5G. With multi-layer demarcation and precise synchronization delivery, the cell site gateway device meets all current mobile network requirements, and its 10Gbit/s capacity enables MNOs to utilize the full 5G spectrum. Its open software-defined networking (SDN) control supports automated network slicing and its pluggable server allows it to be upgraded in-service for edge hosting of VNFs. The ADVA FSP 150-XG118Pro’s capacity and edge hosting capabilities also enable enterprises to unlock the potential of the industrial IoT (IIoT). This makes the solution ideal for a wide range of IIoT business cases that require ultra-low latency and massive machine connectivity.

“This new member of our hugely successful and widely deployed FSP 150 family opens the door to a world of new opportunities. It tears down the entry barriers and provides CSPs and businesses with a risk-free route to all the advantages of virtualization,” commented Ulrich Kohn, director, technical marketing, ADVA. “Featuring our award-winning, field-proven Ensemble Connector NFV hosting software, our FSP 150-XG118Pro enables enterprises to seize the full business potential of the IIoT. It supports big data analytics at the very edge of the network, saving significant bandwidth and improving performance. Now businesses can benefit from our vast experience with migrating centrally hosted network functions to the edge. Our customers can focus on revenue-generating services while we handle complex network integration and testing and ensure superb levels of performance.”

Watch this video for more information on the FSP 150-XG118Pro: http://adva.li/fsp-150-xg118pro-video.

Additional details can also be found in these slides: http://adva.li/fsp-150-xg118pro-slides.

A supporting solution brief can be downloaded here: http://adva.li/connecting-5g-new-radios.


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@advaoptical.com

For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@advaoptical.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye